MX2017003217A - Tratamiento del cancer con el inhibidor de la alfa-amilasa en los animales de compañía. - Google Patents

Tratamiento del cancer con el inhibidor de la alfa-amilasa en los animales de compañía.

Info

Publication number
MX2017003217A
MX2017003217A MX2017003217A MX2017003217A MX2017003217A MX 2017003217 A MX2017003217 A MX 2017003217A MX 2017003217 A MX2017003217 A MX 2017003217A MX 2017003217 A MX2017003217 A MX 2017003217A MX 2017003217 A MX2017003217 A MX 2017003217A
Authority
MX
Mexico
Prior art keywords
cancer
alpha
treatment
companion animal
amylase inhibitor
Prior art date
Application number
MX2017003217A
Other languages
English (en)
Inventor
Pan Yuanlong
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2017003217A publication Critical patent/MX2017003217A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/42—Dry feed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)

Abstract

La invención proporciona métodos para el tratamiento del cáncer, la reducción del riesgo de cáncer o la prevención del cáncer en un animal de compañía, los métodos comprenden: identificar el animal de compañía que tiene cáncer o en riesgo de cáncer y alimentar una formulación dietética en una cantidad terapéuticamente eficaz para el animal. La formulación dietética puede, comprender 20 % a 60 % de proteína; 10 % a 40 % de grasa; 10 % a 50 % de carbohidratos; y 0.01 % a 5 % de inhibidor de la alfa-amilasa, y opcionalmente 1 % a 50 % de almidón resistente. La cantidad terapéuticamente eficaz puede ser eficaz para el tratamiento del cáncer, la prevención del cáncer o la reducción del riesgo de cáncer en el animal de compañía mediante la reducción de la glucosa en sangre postprandial del animal de compañía en comparación con la glucosa en sangre postprandial del animal de compañía que ingiere una formulación dietética comparable que excluye el inhibidor de la alfa-amilasa.
MX2017003217A 2014-09-19 2015-09-17 Tratamiento del cancer con el inhibidor de la alfa-amilasa en los animales de compañía. MX2017003217A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052571P 2014-09-19 2014-09-19
US201462052573P 2014-09-19 2014-09-19
PCT/IB2015/057176 WO2016042518A1 (en) 2014-09-19 2015-09-17 Treatment of cancer with alpha-amylase inhibitor in companion animals

Publications (1)

Publication Number Publication Date
MX2017003217A true MX2017003217A (es) 2017-05-23

Family

ID=54238487

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003217A MX2017003217A (es) 2014-09-19 2015-09-17 Tratamiento del cancer con el inhibidor de la alfa-amilasa en los animales de compañía.

Country Status (12)

Country Link
US (1) US20160082058A1 (es)
EP (1) EP3193897A1 (es)
JP (1) JP2017534576A (es)
CN (1) CN106659791A (es)
AU (1) AU2015319791A1 (es)
BR (1) BR112017003548A2 (es)
CA (1) CA2960347A1 (es)
CL (1) CL2017000578A1 (es)
CO (1) CO2017001899A2 (es)
MX (1) MX2017003217A (es)
RU (1) RU2017113154A (es)
WO (1) WO2016042518A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015316796A1 (en) 2014-09-19 2017-03-30 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as Bub1 inhibitors
EP3326650A1 (en) * 2016-11-28 2018-05-30 Fondazione di Religione e di Culto "Casa Sollievo Della Sofferenza" - Opera di San Pio da Pietrelcina Nutritional composition with resistant starch useful in the treatment of neoplastic diseases
AU2017442089B2 (en) * 2017-12-05 2021-06-03 Hill's Pet Nutrition, Inc. Pet food composition and method of making pet food composition comprising enhanced levels of resistant starch
BR112020024464A2 (pt) * 2018-06-14 2021-03-02 Mars, Incorporated composição de suporte para animal com câncer

Also Published As

Publication number Publication date
BR112017003548A2 (pt) 2017-12-12
RU2017113154A (ru) 2018-10-19
CL2017000578A1 (es) 2017-09-15
CO2017001899A2 (es) 2017-07-28
WO2016042518A1 (en) 2016-03-24
CA2960347A1 (en) 2016-03-24
CN106659791A (zh) 2017-05-10
EP3193897A1 (en) 2017-07-26
US20160082058A1 (en) 2016-03-24
AU2015319791A1 (en) 2017-02-23
JP2017534576A (ja) 2017-11-24

Similar Documents

Publication Publication Date Title
PH12019501448A1 (en) Immunomodulator compounds and methods of use
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
BR112017023269A2 (pt) métodos para tratamento de câncer
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
EA201792547A1 (ru) Популяции бактерий для стимуляции состояния здоровья
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
BR112013006673A2 (pt) produtos terapêuticos para câncer de mama
MX370792B (es) Composiciones para usarse en el tratamiento de cáncer.
BR112018009361A8 (pt) composições e métodos para o tratamento de doenças autoimunes e de câncer
EA201691436A1 (ru) Композиция, включающая окру для применения в уменьшении абсорбции пищевого жира
MX2018002543A (es) Composiciones que comprenden compuestos de urolitina.
MX2020009677A (es) Composiciones preparadas de aves de corral y metodos de su uso.
WO2014079545A8 (en) Thioether derivatives as protein kinase inhibitors
MX2017003217A (es) Tratamiento del cancer con el inhibidor de la alfa-amilasa en los animales de compañía.
BR112017007138A2 (pt) composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto.
NZ733322A (en) Grape products for nonalcoholic fatty liver disease and other uses
MX2017004662A (es) Composiciones y metodos para mejorar la movilidad o actividad o tratar la fragilidad.
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
IN2014DN09240A (es)
MX2017000878A (es) Peptidos marinos y nucleotidos de pescado, composiciones y sus usos para reducir la glucosa en la sangre.
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
MX2017003020A (es) Compuestos de dipeptidil-cetoamida y su uso para el tratamiento y/o la prevencion de la acumulacion de grasa.
MX2017003220A (es) Metodos y formulaciones para reducir la absorcion de carbohidratos en un animal de compañia.
MX2018011512A (es) Uso de insulina para promover el vaciamiento gástrico.